What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “\[203Pb\]VMT-α-NET is administered by intravenous bolus injection for single-photon emission computed tomography imaging.”In the company’s words, NCT05636618 on ClinicalTrials.gov
- Tested for
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma
- Main trialPhase 1/2
- “This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors”In the company’s words, NCT05636618 on ClinicalTrials.gov
Other drugs for Gastroenteropancreatic Neuroendocrine Tumor
- CAM2029Camurus AB · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- 177Lu-edotreotide PRRTITM Solucin GmbH · Phase 3
- CVM-1118TaiRx, Inc. · Phase 2
- Lu-DOTA-TATENovartis Pharmaceuticals · Phase 2
- RYZ401RayzeBio, Inc. · Phase 1
Coming up1
- 26 Nov 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 26 Nov 2029 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026